## Yue Zhao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8926232/publications.pdf

Version: 2024-02-01

		686830	476904
31	963	13	29
papers	citations	h-index	g-index
22	2.2	22	1007
33	33	33	1337
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Subsolid Lesions Exceeding 3 Centimeters: The Ground-Glass Opacity Component Still Matters. Annals of Thoracic Surgery, 2022, 113, 984-992.	0.7	5
2	NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 565-575.	1.2	4
3	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	3.4	30
4	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 221-229.	0.4	2
5	Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 739-747.	1.2	8
6	Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 622723.	1.3	2
7	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	3.4	50
8	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discovery, 2021, 11, 2456-2473.	7.7	74
9	The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types. Frontiers in Oncology, 2021, 11, 645159.	1.3	10
10	A tumor microenvironment-related mRNA–ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3195-3209.	1.2	3
11	Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3144-3154.	1.3	15
12	Integrated analysis of optical mapping and whole-genome sequencing reveals intratumoral genetic heterogeneity in metastatic lung squamous cell carcinoma. Translational Lung Cancer Research, 2020, 9, 670-681.	1.3	11
13	EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1781-1789.	1.2	13
14	Development and validation of a fiveâ€gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. International Journal of Cancer, 2020, 147, 584-592.	2.3	23
15	Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2Âcm or less in diameter. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1603-1613.	1.2	12
16	Risk factors of chylothorax after esophagectomy. Journal of Thoracic Disease, 2019, 11, 1749-1752.	0.6	7
17	Distinct Prognostic Factors in Patients with Stage IÂNon–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions. Journal of Thoracic Oncology, 2019, 14, 2133-2142.	0.5	120
18	Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population. Journal of Thoracic Oncology, 2019, 14, 2003-2008.	0.5	52

#	Article	IF	CITATIONS
19	Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. Journal of Cancer Research and Clinical Oncology, 2019, 145, 747-757.	1.2	8
20	A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2115-2122.	1.2	9
21	Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. Journal of Thoracic Oncology, 2019, 14, 617-627.	0.5	151
22	Proteomic analysis of plasma exosomes to differentiate malignant from benign pulmonary nodules. Clinical Proteomics, 2019, 16, 5.	1.1	15
23	Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nature Communications, 2019, 10, 5472.	5.8	127
24	Preoperative brain MRI for clinical stage IA lung cancer: is routine scanning rational?. Journal of Cancer Research and Clinical Oncology, 2019, 145, 503-509.	1.2	7
25	Direct comparison between video-assisted thoracoscopic surgery and muscle-sparing minithoracotomy in the era of minimally invasive thoracic surgery. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1307-1308.	0.4	0
26	Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. Journal of Cancer Research and Clinical Oncology, 2018, 144, 165-171.	1.2	6
27	Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies. Journal of Thoracic Disease, 2018, 10, 3428-3435.	0.6	14
28	Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma. American Journal of Clinical Pathology, 2018, 150, 65-73.	0.4	31
29	The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 702-709.e1.	0.4	33
30	Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 NO MO lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1420-1429.e1.	0.4	13
31	Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis. Annals of Surgical Oncology, 2016, 23, 2099-2105.	0.7	108